Remepy
hybrid drugs
Biotech
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Remepy going public?
No. Remepy is private and has not filed to go public. There is no S-1 on file.
What is Remepy's valuation in 2026?
No confirmed valuation is on record for Remepy. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Remepy filed an S-1?
No public S-1 is on file for Remepy.
How much has Remepy raised?
Remepy has raised $62M in total across 1 disclosed round, most recently a Series A of $36M in Aug 2026.
Is Remepy publicly traded — can you buy Remepy stock?
No. Remepy is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Remepy on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Last Round
Series A — $36M (Aug 2026)
Fundraising Status
Series A · $36M · 2 mo ago
Total raised $62M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series A | $36M | Aug 2026 | — | — |
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Remepy — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-30. Re-checked weekly.
Talent Signal
No public careers page or job board could be found for Remepy as of 2026-09-23. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.